Axsome Therapeutics (AXSM) Total Liabilities (2021 - 2026)
Axsome Therapeutics' Total Liabilities history spans 6 years, with the latest figure at $659.0 million for Q1 2026.
- On a quarterly basis, Total Liabilities rose 21.26% to $659.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $659.0 million, a 21.26% increase, with the full-year FY2025 number at $601.5 million, up 17.6% from a year prior.
- Total Liabilities hit $659.0 million in Q1 2026 for Axsome Therapeutics, up from $601.5 million in the prior quarter.
- Over the last five years, Total Liabilities for AXSM hit a ceiling of $659.0 million in Q1 2026 and a floor of $73.9 million in Q1 2022.
- Historically, Total Liabilities has averaged $398.5 million across 5 years, with a median of $401.7 million in 2024.
- Biggest five-year swings in Total Liabilities: surged 275.52% in 2023 and later rose 17.6% in 2025.
- Tracing AXSM's Total Liabilities over 5 years: stood at $221.9 million in 2022, then surged by 79.01% to $397.3 million in 2023, then rose by 28.75% to $511.5 million in 2024, then rose by 17.6% to $601.5 million in 2025, then increased by 9.56% to $659.0 million in 2026.
- Business Quant data shows Total Liabilities for AXSM at $659.0 million in Q1 2026, $601.5 million in Q4 2025, and $595.5 million in Q3 2025.